Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic

Background/aim: To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6–9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients’ data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: A total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21–73] vs. 44 years [20–79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored.Key words: COVID-19, biologic DMARDs, rheumatoid arthritis, spondyloarthritis

PDF

___

1. Carrillo-Vega MF, Salinas-Escudero G, Garcia-Pena C, Gutierrez-Robledo LM, Parra-Rodriguez L. Early estimation of the risk factors for hospitalization and mortality by COVID-19 in Mexico. Plos One 2020; 15 (9): e0238905. Doi: 10.1371/ journal.pone.0238905
2. Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the Rheumatic Diseases 2020; 79 (7): 859- 866. Doi: 10.1136/annrheumdis-2020-217871
3. Noor FM, Islam MM. Prevalence and associated risk factors of mortality among COVID-19 patients: a meta-analysis. Journal of Community Health 2020; 45 (6): 1270-1282. doi: 10.1007/ s10900-020-00920-x
4. Landewe RB, Machado PM, Kroon F, Bijlsma HW, Burmester GR et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-cov-2. Annals of the Rheumatic Diseases 2020; 79 (7): 851-858. doi: 10.1136/annrheumdis-2020-217877
5. Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2. Arthritis and Rheumatology 2020; 72 (9): e1-e12. doi: 10.1002/art.41437
6. Babaoglu H. Türkiye Romatoloji Derneği Romatoloji uzmanlari için koronavirüs (Covid-19) salgını sırasında hastalık yönetimi önerileri. Journal of Turkish Society of Rheumatology 2020; 12 (1):1-2 (in Turkish). doi: 10.4274/raed.galenos.2020.99609
7. Kalyoncu U, Tascilar EK, Ertenli AI, Dalkilic HE, Bes C et al. Methodology of a new inflammatory arthritis registry: treasure. Turkish Journal of Medical Sciences 2018; 48 (4): 856- 861. doi: 10.3906/sag-1807-200
8. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis and Rheumatology 1984; 27 (4): 361-368. doi: 10.1002/ art.1780270401
9. Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N et al. The development of Assessment of spondyloarthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Annals of the Rheumatic Diseases 2009; 68 (6): 777-783. doi:
10.1136/ard.2009.108233 10. Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J et al. The Assessment of spondyloarthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Annals of the Rheumatic Diseases 2011; 70 (1): 25-31. doi: 10.1136/ard.2010.133645
11. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis and Rheumatology 2006; 54 (8): 2665-2673. doi: 10.1002/art.21972
12. Esatoglu SN, Tascilar K, Babaoglu H, Bes C, Yurttas B et al. COVID-19 among patients with inflammatory rheumatic diseases, PREPRINT (Version 1) available at Research Square. Dec 2020. doi: 10.21203/rs.3.rs-115378/v1
13. Favalli EG, Monti S, Ingegnoli F, Balduzzi S, Caporali R et al. Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Arthritis and Rheumatology 2020; 72 (10): 1600-1606. doi: 10.1002/art.41388